Effects of microRNA-101-3p on predicting pediatric acute respiratory distress syndrome and its role in human alveolar epithelial cell

Bioengineered. 2022 May;13(5):11602-11611. doi: 10.1080/21655979.2022.2070583.

Abstract

Pediatric acute respiratory distress syndrome (PARDS) is a severe form of respiratory failure associated with high mortality among children. The objective of this study is reported to explore the clinical function and molecular roles of microRNA-101-3p (miR-101-3p) in PARDS. The levels of miR-101-3p and mRNA levels of SRY-related high-mobility group box 9 (Sox9) were measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Additionally, the diagnostic role of miR-101-3p was identified by using the Receiver operating characteristic (ROC) curve. The cell proliferation and apoptosis were examined through Cell Counting Kit-8 (CCK-8) assay and flow cytometry. To detect inflammation in cells, enzyme-linked immunosorbent assays (ELISA) were performed. The target gene of miR-101-3p was confirmed through data obtained from the luciferase activity. In patients with PARDS, miR-101-3p expression was decreased. Moderate and severe PARDS patients had lower levels of miR-101-3p than mild PARDS patients. The inflammatory progression was related to the aberrant expression of miR-101-3p in all PARDS children. MiR-101-3p was highly predictive for the detection of children with PARDS. In addition, miR-101-3p might protect A549 cells from abnormal proliferation, apoptosis, and inflammation caused by lipopolysaccharide (LPS). Sox9 might be a target gene of miR-101-3p and increased mRNA expression of Sox9 in LPS-treated A549 cells was inhibited by overexpression of miR-101-3p. Ultimately, this study suggested that reduced expression of miR-101-3p plays a role in PARDS, providing a novel angle to study the disease.

Keywords: PARDS; diagnosis; inflammation; miR-101-3p; sox9.

MeSH terms

  • Alveolar Epithelial Cells / metabolism
  • Child
  • Humans
  • Inflammation
  • Lipopolysaccharides / pharmacology
  • MicroRNAs* / metabolism
  • RNA, Messenger
  • Respiratory Distress Syndrome* / diagnosis
  • Respiratory Distress Syndrome* / genetics

Substances

  • Lipopolysaccharides
  • MIRN101 microRNA, human
  • MicroRNAs
  • RNA, Messenger

Grants and funding

This research was funded by the Hunan Provincial Health and Health Commission Project. [Grant number: 202202074054]